Investigating the association (assoc) between mental health illness (MHI) and development of prostate cancer (PC) in a nationwide matched cohort of >5,000,000 US Veterans.

Authors

Zachary Klaassen

Zachary Klaassen

Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA

Zachary Klaassen , Jessica Janes , Joshua Parrish , Rashid K. Sayyid , Sydney McIntire , Amanda Marie De Hoedt , Raj Satkunasivam , Stephen B. Williams , Christopher J.D. Wallis , Martha K. Terris , Stephen J. Freedland

Organizations

Division of Urology, Medical College of Georgia, Augusta University, Augusta, GA, Durham VA Health Care System, Durham, NC, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada, Durham VA, Durham, NC, Institute for Medical Research, Durham VA Health Care System, Durham, NC, Department of Urology, Houston Methodist Hospital, Houston, TX, University of Texas Medical Branch at Galveston, Galveston, TX, Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada, Augusta University Medical Center, Augusta, GA, Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA

Research Funding

Other Government Agency
Department of Defense Career Development Award

Background: Previous reports suggest that men with MHI who subsequently develop PC have worse outcomes. However, it has not been established whether a history of MHI is associated with a PC diagnosis (dx) or more aggressive PC. The objective of this study was to (i) investigate the assoc between MHI and development of PC, and (ii) in a subset of men with available Gleason Score (GS) data, assess the assoc between MHI and aggressive PC as measured by GS ≥7 PC at dx. Methods: This was a retrospective matched-cohort analysis to assess the assoc between MHI and time to PC dx in the Veterans Affairs (VA) Health Care System. Men with an ICD code for MHI dx between 2000-2020 were matched 1:1 to men with no MHI dx in the same time frame. The MHI dx date of the exposed (exp) male was assigned as the index date of the unexp male. Variables matched on included race, age at MHI exp (+/- 3 years), census region, and median household income. Uni- and multivariable competing risks models were used to test the assoc between MHI and time to PC using death from other causes as competing risk. In a subset of men with GS data available, logistic regression was used to test the assoc between MHI and GS ≥7 at PC dx. All multivariable models were adjusted for age, race, census region, income, Charlson Comorbidity Index, year of MHI index, and year of VA entry. Results: There were 2,597,810 MHI-exp men matched 1:1 to unexp men. During a median (Q1, Q3) follow up of 128 (65, 192) months, 390,977 PC diagnoses were observed (172,442 MHI-exp vs. 218,535 unexp). MHI-exp men were significantly less likely to be diagnosed with PC than unexp men in both uni- (HR: 0.798, 95% CI: 0.793-0.803) and multivariable (HR: 0.763, 95% CI: 0.758-0.768) analysis. Cumulative incidence estimates at 3, 5, 10, and 20 years were 2.1%, 3.1%, 5.2%, and 8.5%, respectively, for MHI-exp men vs 2.9%, 4.2%, 6.9%, and 11.7%, respectively, for unexp men. Among men with PC and available GS data (n = 51,404), 32,645 had GS ≥7 PC, of which 20,749 were MHI-exp vs 11,896 unexp. MHI-exp men had significantly higher odds of GS ≥7 PC in both uni- (OR: 2.38, 95% CI: 2.32-2.43) and multivariable (OR: 1.97, 95% CI: 1.92-2.02) analysis. Conclusions: Men with MHI are 20% less likely to be diagnosed with PC, however when diagnosed, are nearly 2 times more likely to have aggressive PC compared to non-MHI men. Although speculative based on the nature of the study, this may be due to poorer access to preventative health services resulting in delayed diagnoses.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Publication Only

Session Title

Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Other Prostate, Testicular, or Penile Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr e17113)

DOI

10.1200/JCO.2023.41.16_suppl.e17113

Abstract #

e17113

Abstract Disclosures

Similar Abstracts

First Author: Rana R. McKay

Abstract

2023 ASCO Quality Care Symposium

Evaluating the teleoncology experience of veterans with prostate cancer: A qualitative study.

First Author: Divya Ahuja Parikh

First Author: Joshua Mabellos